Cargando…
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
The clinical outcome of T-cell non-Hodgkin lymphoma (NHL) is poor and innovative treatments are needed. Tenascin-C is a large extracellular glycoprotein not expressed under physiological conditions, but overexpressed in cancer. Aim of the study was to evaluate tenascin-C expression within pathologic...
Autores principales: | Gritti, Giuseppe, Gianatti, Andrea, Petronzelli, Fiorella, De Santis, Rita, Pavoni, Chiara, Rossi, Riccardo Lorenzo, Cattaneo, Laura, Spagnoli, Luigi Giusto, Ferrari, Silvia, Rossi, Andrea, Barbui, Anna Maria, Rambaldi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5839400/ https://www.ncbi.nlm.nih.gov/pubmed/29515769 http://dx.doi.org/10.18632/oncotarget.23919 |
Ejemplares similares
-
Correction: Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritt, Giuseppe, et al.
Publicado: (2018) -
Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas
por: Gritti, Giuseppe, et al.
Publicado: (2015) -
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival
por: Tarella, Corrado, et al.
Publicado: (2014) -
Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013) -
Is There a Role for Minimal Residual Disease Monitoring in Follicular Lymphoma in the Chemo-Immunotherapy Era?
por: Gritti, Giuseppe, et al.
Publicado: (2017)